🇺🇸 PF-05280586 in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 11

Most-reported reactions

1. Febrile Neutropenia — 3 reports (27.27%)
2. Neoplasm — 2 reports (18.18%)
3. Acute Myeloid Leukaemia — 1 report (9.09%)
4. Aspergillus Infection — 1 report (9.09%)
5. Intentional Product Use Issue — 1 report (9.09%)
6. Monocytosis — 1 report (9.09%)
7. Syncope — 1 report (9.09%)
8. Urinary Tract Infection — 1 report (9.09%)

Source database →

Frequently asked questions

Is PF-05280586 approved in United States?

PF-05280586 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for PF-05280586 in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.